FitFlow review

What it is

FitFlow, trading as FitFlow Health at fitflowrx.com, is a 100% online telehealth platform organised around weight loss, strength, anti-aging, hair growth and mood. Its named products include compounded semaglutide and tirzepatide, sermorelin, an NAD⁺ injection, an NAD⁺ facial cream, glutathione and MIC+B12, with hair and sexual-health lines alongside. Intake is a five-to-ten-minute HIPAA-compliant questionnaire reviewed by a board-certified provider within a stated 24 to 48 hours, after which medication ships free and discreetly from a US-licensed compounding pharmacy in five to seven days. It advertises FSA/HSA eligibility, financing through Affirm, Klarna and Afterpay, unlimited messaging, dose adjustments and cancel-anytime terms.

How it works

Asynchronous, fast and low-friction: a short questionnaire, provider review inside a day or two, then shipping, with unlimited messaging and dose adjustments included in the plan. Unlimited messaging is a real inclusion rather than a marketing line — for a peptide where the sensible question is whether your dose is doing anything, having a route back to a clinician without a new charge matters. What the default path does not include is lab work of any kind, which is worth pausing on for sermorelin: an IGF-1 baseline is the obvious measurement to take before starting a growth-hormone secretagogue and to repeat afterwards, and here you would need to arrange it yourself. The disclosure gaps are consistent and they are all of the same type. The compounding pharmacy is described as US-licensed and FDA-regulated but never named. No state-availability list is published behind a nationwide-shipping claim. No LegitScript or equivalent certification is displayed. And no operating legal entity beyond the brand name appears on the site. None of that is disqualifying on its own; together it means the pricing is the only thing you can actually check.

Pricing transparency

Published for the molecules this board is about, which is the case for listing FitFlow at all. Sermorelin is from $175 a month, the NAD⁺ injection from $165, and glutathione is offered without a shelf price on the same page. Both peptide figures were absent from the record we started with and appear on the live site now. On the GLP-1 side, month-to-month rates are $175 for semaglutide and $235 for tirzepatide, falling on prepay to $145 and $199 quarterly, $120 and $175 at six months, and $99 and $125 on an annual plan requiring $1,188 or $1,500 up front — the advertised headline rates are the annual-prepay ones, which is a marketing choice worth reading carefully before you assume the peptide pricing works the same way. Ask whether the sermorelin and NAD⁺ figures are month-to-month or prepay rates, what dose and quantity each supplies, and whether the price rises as the dose escalates. Shipping is free and the platform advertises no hidden fees and cancellation at any time.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. FitFlow discloses the compounded status of its medications and describes US-licensed compounding pharmacies, but names none, and compounded sterile products are not reviewed by FDA for purity and potency the way approved drugs are. On the evidence, the two priced peptides sit at different places and the site does not distinguish them. Sermorelin is a GHRH analogue acting on the growth-hormone axis — a real, well-described mechanism — but long-term human outcome data stays thin and no controlled trial demonstrates the body-composition, recovery or anti-aging results the category is marketed on. NAD⁺ by injection is weaker still: no controlled human outcome trials exist for it at all, and the single human intravenous study was a pharmacokinetic pilot finding that infused NAD⁺ clears from plasma quickly. The NAD⁺ forms with human data are the oral precursors NR and NMN, which reliably raise blood NAD⁺ — a raised biomarker rather than a demonstrated clinical benefit — and the NAD⁺ facial cream FitFlow also sells has no outcome evidence behind it whatsoever. Glutathione is in the same position. On the GLP-1 side, compounded semaglutide and tirzepatide target well-studied pathways but the compounded preparations are not themselves FDA-approved or therapeutically equivalent to Wegovy, Ozempic, Zepbound or Mounjaro. Individual results vary.

Pros and watch-outs

The evidence behind what FitFlow prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

How FitFlow compares

A few alternatives worth a look, depending on what you’re optimizing for.

• CoreAge Rx

  Injected or intranasal NAD⁺ at a published price across 50 states

  See CoreAge Rx →
• LHLuvo Health

  Prescription NAD⁺ as an injection, drops or nasal spray at one flat price

  See Luvo Health →
• Telos RX

  Choice of GLP-1 formats, including needle-free sublingual tirzepatide

  See Telos RX →